The ROSlow AML CD34+ cells exhibited long-term expansion in comparison with the ROShigh CD34+ cells (week 5; ROSlow 7.1-fold±2.1 versus ROShigh 1.6-fold±0.4 (n=6, P≤0.05)). Here, CD34 is linked to acute myeloid leukemia.